| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
in Human Preeclamptic and Growth-Restricted Placentas
The Sir Quinton Hazel Research Centre for Molecular Medicine, Department of Biological Sciences (E.Ka., E.W.H., D.K.G.), University of Warwick, Coventry CV4 7AL, United Kingdom; and University of Crete, Division of Medicine, Department of Obstetrics and Gynecology (A.G., E.Ko.), Heraklion, Crete, Greece 71110
Address all correspondence and requests for reprints to: Dr. D. K. Grammatopoulos, Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, United Kingdom. E-mail: dgrammatopoulos{at}bio.warwick.ac.uk.
Placentally derived CRH seems to play a major role in the mechanisms controlling human pregnancy and parturition, via activation of specific receptors widespread in reproductive tissues. In the human placenta, CRH seems to modulate vasodilation, prostaglandin production, and ACTH secretion. It has also been suggested that CRH might act as a placental clock, determining the length of gestation. In addition, maternal plasma CRH concentrations are further elevated in pregnancies associated with abnormal placental function, such as preeclampsia and intrauterine growth retardation (IUGR).
In this study, we sought to investigate the expression of CRH-R1
levels in placentas from women who have undergone normal deliveries (control group) and patients who have been diagnosed as having preeclampsia or IUGR. Results showed that placental CRH-R1
mRNA levels (as shown by quantitative RT-PCR) and protein levels (shown by Western blotting analysis) were significantly (P < 0.05) reduced in all of the complicated pregnancies. In contrast, levels of the angiotensin II receptor were elevated in preeclampsia and reduced in IUGR subjects, as shown by RT-PCR and Western blotting analysis. These findings might suggest that changes in receptor expression may contribute toward dysregulation of the dynamic balance controlling vascular resistance.
This study was funded by Wellcome Trust. D.K.G. is a Wellcome Trust Career Development Research Fellow.
Abbreviations: AT1-R, Angiotensin II receptor; B2, bradykinin B2; CRH-R, CRH receptor; SDS, sodium dodecyl sulfate; IUGR, intrauterine growth retardation.
This article has been cited by other articles:
![]() |
L. Gao, C. Lu, C. Xu, Y. Tao, B. Cong, and X. Ni Differential Regulation of Prostaglandin Production Mediated by Corticotropin-Releasing Hormone Receptor Type 1 and Type 2 in Cultured Human Placental Trophoblasts Endocrinology, June 1, 2008; 149(6): 2866 - 2876. [Abstract] [Full Text] [PDF] |
||||
![]() |
Dan Jin, Ping He, Xingji You, Xiaoyan Zhu, Ling Dai, Qian He, Chunmin Liu, Ning Hui, Jinyan Sha, and Xin Ni Expression of Corticotropin-Releasing Hormone Receptor Type 1 and Type 2 in Human Pregnant Myometrium Reproductive Sciences, September 1, 2007; 14(6): 568 - 577. [Abstract] [PDF] |
||||
![]() |
L. Gao, P. He, J. Sha, C. Liu, L. Dai, N. Hui, and X. Ni Corticotropin-Releasing Hormone Receptor Type 1 and Type 2 Mediate Differential Effects on 15-Hydroxy Prostaglandin Dehydrogenase Expression in Cultured Human Chorion Trophoblasts Endocrinology, August 1, 2007; 148(8): 3645 - 3654. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Hillhouse and D. K. Grammatopoulos The Molecular Mechanisms Underlying the Regulation of the Biological Activity of Corticotropin-Releasing Hormone Receptors: Implications for Physiology and Pathophysiology Endocr. Rev., May 1, 2006; 27(3): 260 - 286. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Bamberger, V. Minas, S. N. Kalantaridou, J. Radde, H. Sadeghian, T. Loning, I. Charalampopoulos, J. Brummer, C. Wagener, C. M. Bamberger, et al. Corticotropin-Releasing Hormone Modulates Human Trophoblast Invasion through Carcinoembryonic Antigen-Related Cell Adhesion Molecule-1 Regulation Am. J. Pathol., January 1, 2006; 168(1): 141 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Li and J. R. G. Challis Corticotropin-Releasing Hormone and Urocortin Induce Secretion of Matrix Metalloproteinase-9 (MMP-9) without Change in Tissue Inhibitors of MMP-1 by Cultured Cells from Human Placenta and Fetal Membranes J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6569 - 6574. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cao, N. Papadopoulou, D. Kempuraj, W. S. Boucher, K. Sugimoto, C. L. Cetrulo, and T. C. Theoharides Human Mast Cells Express Corticotropin-Releasing Hormone (CRH) Receptors and CRH Leads to Selective Secretion of Vascular Endothelial Growth Factor J. Immunol., June 15, 2005; 174(12): 7665 - 7675. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Karteris, M. Vatish, E. W. Hillhouse, and D. K. Grammatopoulos Preeclampsia Is Associated with Impaired Regulation of the Placental Nitric Oxide-Cyclic Guanosine Monophosphate Pathway by Corticotropin-Releasing Hormone (CRH) and CRH-Related Peptides J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3680 - 3687. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Papadopoulou, J. Chen, H. S. Randeva, M. A. Levine, E. W. Hillhouse, and D. K. Grammatopoulos Protein Kinase A-Induced Negative Regulation of the Corticotropin-Releasing Hormone R1{alpha} Receptor-Extracellularly Regulated Kinase Signal Transduction Pathway: The Critical Role of Ser301 for Signaling Switch and Selectivity Mol. Endocrinol., March 1, 2004; 18(3): 624 - 639. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |